Pair Name	Nimbolide, Docetaxel
Partner Name	Docetaxel
Disease Info	[ICD-11: 2C82.0]	Prostate cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Activity	NFKB1	hsa4790
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	LNCaP	Prostate carcinoma	Homo sapiens (Human)	CVCL_0395
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	PC-3 D12	Prostate carcinoma	Homo sapiens (Human)	CVCL_4Y40
In Vivo Model	8-week-old male SCID mice were orthotopically implanted with LNCaP-Luc or PC-3-Luc cells to induce tumors.
Result	The combination of NL and DTX significantly reduced the DNA binding ability of NF-κB in both cell types. NL significantly enhanced the antitumor effect of DTX and reduced metastases in orthotopic models of prostate cancer. NL abolishes DTX-induced-NF-κB activation to counteract cell proliferation, tumor growth, and metastasis in the prostate cancer models.

Pair Name	Nimbolide, Tumor necrosis factor-alpha
Partner Name	Tumor necrosis factor-alpha
Disease Info	[ICD-11: 2B90.Z]	Colon cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BID	hsa637
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Up-regulation	Expression	TNFRSF10B	hsa8795
In Vitro Model	HT-29	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0320
Result	Our findings overall indicate that nimbolide may enhance TNF-α-mediated cellular proliferation inhibition through increasing cell apoptosis of HT-29 cells by up-reglation of DR5 expression via the JNK pathway.